Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › 2026 Clinical Trial Readout Calendar

2026 Clinical Trial Readout Calendar

Upcoming Phase 1/2/3 data readouts — company, drug, indication, and the registered trial. Dates are estimated primary-completion windows from ClinicalTrials.gov, not fixed announcements — they shift. Tap any row for the trial record.

PDUFA dates Trial readouts Devices

June 2026

BMY · 2026-06-25

- — Advanced Cancer

SNY · 2026-06-29

- — Dermatitis Atopic

AGIO · 2026-06-30

Mitapivat Matched Placebo — Anemia

BCAB · 2026-06-30

- — Ovarian Cancer

CELC · 2026-06-30

Palbociclib — Breast Cancer

CLLS · 2026-06-30

UCART22 — B-cell Acute Lymphoblastic Leukemia

LGVN · 2026-06-30

- — Hypoplastic Left Heart Syndrome

OLMA · 2026-06-30

Palazestrant — Breast Cancer

July 2026

AXS-14 — Major Depressive Disorder (MDD)

CALC · 2026-07-01

CM4620 — Acute Kidney Injury

CGTX · 2026-07-01

Dextromethorphan-Bupropion — Major Depressive Disorder (MDD)

CLYM · 2026-07-01

Budoprutug — Healthy Volunteers

PYXS · 2026-07-01

PYX-201 — Solid Tumor

RARE · 2026-07-01

GTX-102 — Angelman Syndrome

SION · 2026-07-01

SION-719 — Cystic Fibrosis (CF)

STTK · 2026-07-01

- — Healthy Volunteers

IOVA · 2026-07-01

Lifileucel plus Pembrolizumab — Soft Tissue Sarcoma

IBRX · 2026-07-01

- — Long COVID

HOWL · 2026-07-01

WTX-330 — Metastatic Solid Tumor

GLUE · 2026-07-01

Oral MRT-2359 — Healthy Volunteers

EVMN · 2026-07-01

EVO756 — Atoptic Dermatitis

DWTX · 2026-07-01

Halneuron — Chemotherapy Induced Neuropathic Pain

BNTX · 2026-07-23

- — SARS-CoV-2 Virus

LTRN · 2026-07-28

BNP7787 — Advanced Solid Tumor

BNTX · 2026-07-31

- — COVID-19

ONC · 2026-07-31

Tislelizumab — Gastric Neoplasms

IBRX · 2026-07-31

- — Head and Neck Cancer

August 2026

ABBV · 2026-08-01

RGX-314 — Neovascular Age-Related Macular Degeneration (nAMD)

ACIU · 2026-08-01

- — Healthy Participants

ACRS · 2026-08-01

A-101 — Atopic Dermatitis

BIVI · 2026-08-01

NE3107 — Long COVID

BNTX · 2026-08-01

- — CRC (Colorectal Cancer)

CADL · 2026-08-01

Aglatimagene besadenovec + valacyclovir — Prostate Cancer Patients Treated by Radiotherapy

CRIS · 2026-08-01

chondrocyte-alginate gel suspension — Relapsed Hematologic Malignancy

MANE · 2026-08-01

VDPHL01 — Androgenetic Alopecia

MIRM · 2026-08-01

Brelovitug — Chronic Hepatitis D Infection

NCNA · 2026-08-01

NUC-1031 — Advanced Cancer

RCUS · 2026-08-01

- — Head and Neck Squamous Cell Carcinoma

RGNX · 2026-08-01

Ranibizumab — Neovascular Age-Related Macular Degeneration (nAMD)

- — Obesity & Overweight

XENE · 2026-08-01

Azetukalner — Major Depressive Disorder

KPTI · 2026-08-01

Selinexor — Endometrial Cancer

KOD · 2026-08-01

Tarcocimab Tedromer — Wet Age-related Macular Degeneration

IVVD · 2026-08-01

VYD2311 — COVID-19

GPCR · 2026-08-01

aleniglipron — Obesity, Overweight, or Chronic Weight Management

GILD · 2026-08-01

- — Head and Neck Squamous Cell Carcinoma

EYPT · 2026-08-01

EYP-1901 — Wet Age Related Macular Degeneration

ENSC · 2026-08-01

PF614 capsule — Postoperative Pain, Acute

JNJ · 2026-08-02

- — Glioblastoma

MRK · 2026-08-05

Ensifentrine — Chronic Obstructive Pulmonary Disease

SNY · 2026-08-05

- — Coeliac Disease

MBIO · 2026-08-06

- — Adult Acute Myeloid Leukemia in Remission

JSPR · 2026-08-13

Briquilimab — Urticaria Chronic

PMVP · 2026-08-15

rezatapopt — Advanced Solid Tumor

SYRE · 2026-08-19

SPY001 — Healthy

CLRB · 2026-08-25

NOV-002 — Pediatric Solid Tumor

GILD · 2026-08-28

- — Disseminated Histoplasma Capsulatum Infection

MSLE · 2026-08-30

SAT-3247 — Duchenne Muscular Dystrophy (DMD)

NRIX · 2026-08-31

NX-5948 — Ovarian Cancer, Epithelial

VSTM · 2026-08-31

avutometinib — KRAS Activating Mutation

September 2026

Topical Roflumilast — Hidradenitis Suppurativa

ARVN · 2026-09-01

ARV-471 — Breast Cancer

AVIR · 2026-09-01

Bemnifosbuvir-Ruzasvir — HEPATITIS C VIRUS CHRONIC INFECTION

BHVN · 2026-09-01

Taldefgrobep Alfa — Obesity

CGEM · 2026-09-01

CLN-081 — Multiple Myeloma

CRVO · 2026-09-01

Neflamapimod — Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

NVCR · 2026-09-01

Temozolomide — Anaplastic (Malignant) Meningioma

NVO · 2026-09-01

- — Chronic Kidney Disease

PFE · 2026-09-01

- — Breast Cancer

RAPP · 2026-09-01

RAP-219 — Bipolar 1 Disorder

SLN · 2026-09-01

SLN124 — Polycythemia Vera

SUPN · 2026-09-01

SPN-812 — Attention-Deficit/Hyperactivity Disorder

TRAW · 2026-09-01

rigosertib — Healthy Volunteer

TYRA · 2026-09-01

Dabogratinib — Locally Advanced Cholangiocarcinoma

VERA · 2026-09-01

Atacicept — IgA Nephropathy (IgAN)

KPTI · 2026-09-01

Selinexor — Myelofibrosis

IRON · 2026-09-01

DISC-1459 — Myelofibrosis; Anemia

IOVA · 2026-09-01

Lifileucel plus Pembrolizumab — Gastric Cancer

GPCR · 2026-09-01

aleniglipron — Obese

EWTX · 2026-09-01

- — Becker Muscular Dystrophy

DSGN · 2026-09-01

DT-168 — Fuchs Endothelial Corneal Dystrophy

CRDL · 2026-09-21

CardiolRx — Recurrent Pericarditis

VIR · 2026-09-25

VIR-2218 — Hepatic Impairment

MLTX · 2026-09-28

Sonelokimab — Hidradenitis Suppurativa

ALEC · 2026-09-30

Latozinemab — Alzheimer's Disease

CCCC · 2026-09-30

Cemsidomide — Multiple Myeloma

CHRS · 2026-09-30

CHS-1420 — Advanced Solid Tumor

IBRX · 2026-09-30

ALT-803 — Non-muscle Invasive Bladder Cancer

October 2026

ABBV · 2026-10-01

- — AMD

AGEN · 2026-10-01

Balstilimab — Anatomic Stage IV Breast Cancer AJCC v8

COCP · 2026-10-01

CDI-988 — Norovirus

CRNX · 2026-10-01

Atumelnant — Cushing Syndrome

MIRM · 2026-10-01

Maralixibat — Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

NTRA · 2026-10-01

- — Locally Advanced Rectal Carcinoma

OGN · 2026-10-01

Tapinarof cream, — Plaque Psoriasis

PFE · 2026-10-01

- — Endometrial Cancer

RGNX · 2026-10-01

Ranibizumab — AMD

TENX · 2026-10-01

TNX-103 — Pulmonary Hypertension

VTRS · 2026-10-01

- — Chronic Coronary Syndrome

XENE · 2026-10-01

Azetukalner — Focal Onset Seizures

JBIO · 2026-10-01

JADE101 — Healthy Volunteers

IRON · 2026-10-01

DISC-1459 — Inflammatory Bowel Disease (IBD)

IOVA · 2026-10-01

Lifileucel plus Pembrolizumab — HPV-Associated Cervical Carcinoma

IBRX · 2026-10-01

- — Long COVID

HUMA · 2026-10-01

Human Acellular Vessel — End Stage Renal Disease (ESRD)

EYPT · 2026-10-01

EYP-1901 — Wet Age Related Macular Degeneration

SLDB · 2026-10-15

SGT-003 — Duchenne Muscular Dystrophy

INBX · 2026-10-30

INBRX-106 — Solid Tumor

ADAG · 2026-10-31

Pembrolizumab — Advanced/Metastatic Solid Tumors

ANNX · 2026-10-31

Tanruprubart — Geographic Atrophy

MRK · 2026-10-31

IMG-7289 — Essential Thrombocythemia

RCUS · 2026-10-31

Domvanalimab — Non Small Cell Lung Cancer

RYTM · 2026-10-31

Setmelanotide — Prader-Willi Syndrome

SRPT · 2026-10-31

Eteplirsen — Muscular Dystrophy, Duchenne

SYRE · 2026-10-31

SPY001 — Rheumatoid Arthritis

TGTX · 2026-10-31

- — Relapsing Multiple Sclerosis

VTRS · 2026-10-31

Cenerimod — Lupus Erythematosus, Systemic

JSPR · 2026-10-31

Briquilimab — Chronic Spontaneous Urticaria

November 2026

ANL · 2026-11-01

Buparlisib & Paclitaxel — Advanced Solid Tumor

APGE · 2026-11-01

APG777 — Atopic Dermatitis

ATOS · 2026-11-01

Z-Endoxifen — Breast Neoplasms

BHVN · 2026-11-01

BHV-7000 — Familial Erythromelalgia

BNTX · 2026-11-01

- — Colorectal Cancer Stage II

BYSI · 2026-11-01

Docetaxel + Plinabulin — Multiple Myeloma

CGEM · 2026-11-01

CLN-081 — NHL

DFTX · 2026-11-01

DT120 — Generalized Anxiety Disorder

TRAW · 2026-11-01

rigosertib — Influenza

TYRA · 2026-11-01

Dabogratinib — Locally Advanced Urothelial Carcinoma

VIR · 2026-11-01

Bulevirtide — Viral Hepatitis

KPRX · 2026-11-01

KIO-104 — Macular Edema

IOVA · 2026-11-01

Lifileucel plus Pembrolizumab — Metastatic Melanoma

IBRX · 2026-11-01

- — Non-muscle Invasive Bladder Cancer (NMIBC)

ENTA · 2026-11-01

- — Chronic Inducible Urticaria

SNY · 2026-11-05

- — Hemophilia

PGEN · 2026-11-11

PRGN-2009 — Cervical Cancer

SYRE · 2026-11-18

SPY001 — Healthy

SKYE · 2026-11-20

SBI-100 Ophthalmic Emulsion, — Obesity

BIOA · 2026-11-30

BGE-102 — Obesity and Cardiovascular Risk

SNY · 2026-11-30

- — Plasma Cell Myeloma

December 2026

ABX464 — Moderately to Severely Active Crohn Disease

AGEN · 2026-12-01

Balstilimab — Refractory Metastatic Colorectal Cancer

ALDX · 2026-12-01

- — Primary Vitreoretinal Lymphoma

ALMS · 2026-12-01

Envudeucitinib — Plaque Psoriasis

ALZN · 2026-12-01

AL001 — Bipolar I Disorder

APGE · 2026-12-01

APG777 — Atopic Dermatitis

AVIR · 2026-12-01

Bemnifosbuvir-Ruzasvir — HEPATITIS C VIRUS CHRONIC INFECTION

AXSM · 2026-12-01

AXS-14 — Excessive Sleepiness

BCDA · 2026-12-01

Autologous cell therapy — Heart Failure, Systolic

BEAM · 2026-12-01

BEAM-302 — Lymphoblastic Lymphoma

BHVN · 2026-12-01

BHV-7000 — Focal Epilepsy

CGEM · 2026-12-01

CLN-081 — SLE

CNTA · 2026-12-01

cleminorexton — Narcolepsy Type 1

CNTX · 2026-12-01

Onapristone ER — Mesothelin-Expressing Tumors

DCTH · 2026-12-01

Cisplatin and Gemcitabine — Refractory Metastatic Colorectal Cancer

KYMR · 2026-12-01

KT-621 — Healthy Participants

LTRN · 2026-12-01

BNP7787 — Adenocarcinoma of Lung

MANE · 2026-12-01

VDPHL01 — Androgenetic Alopecia

MDGL · 2026-12-01

Resmetirom — NASH

MDWD · 2026-12-01

EscharEx — Venous Leg Ulcer (VLU)

MNPR · 2026-12-01

Clonidine HCl Mucoadhesive Buccal Tablet — Solid Tumor, Adult

MRK · 2026-12-01

Ensifentrine — COPD

NTRA · 2026-12-01

- — Colon Adenocarcinoma

NVCT · 2026-12-01

- — EGFR Mutation Positive Non-small Cell Lung Cancer

NXTC · 2026-12-01

- — Ovarian Cancer

PBYI · 2026-12-01

neratinib — Breast Cancer

PHAT · 2026-12-01

Vonoprazan — Eosinophilic Esophagitis

PMN · 2026-12-01

- — Alzheimer Disease, Early Onset

RCUS · 2026-12-01

Quemliclustat — Borderline Resectable Pancreatic Adenocarcinoma

RGNX · 2026-12-01

Ranibizumab — AMD

SNDX · 2026-12-01

Revumenib — Acute Myeloid Leukemia

TEM · 2026-12-01

A2B530 — Solid Tumor, Adult

TRAW · 2026-12-01

rigosertib — Influenza

TVTX · 2026-12-01

Pegtibatinase — Proteinuric Renal Disease

VIR · 2026-12-01

Tobevibart — Viral Hepatitis

VTRS · 2026-12-01

- — Acute Myocardial Infarction

ZNTL · 2026-12-01

Investigator's choice of Chemotherapy — High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

ZYME · 2026-12-01

- — Advanced Solid Tumors

KRYS · 2026-12-01

KB803 — Cystic Fibrosis

KPTI · 2026-12-01

KPT-330 — Diffuse Large B-cell Lymphoma

IONS · 2026-12-01

Donidalorsen — Hereditary Angioedema

IMMX · 2026-12-01

NXC-201 CAR-T — Light Chain (AL) Amyloidosis

GOSS · 2026-12-01

Seralutinib — Pulmonary Arterial Hypertension

GLSI · 2026-12-01

GLSI-100 — Breast Cancer

GILD · 2026-12-01

- — Multiple Myeloma

EPRX · 2026-12-01

EP-104GI — Eosinophilic Esophagitis

ENTA · 2026-12-01

Zelicapavir — RSV Infection

DSGN · 2026-12-01

DT-168 — Friedreich Ataxia

DNLI · 2026-12-01

- — Frontotemporal Dementia

DMAC · 2026-12-01

Recombinant human tissue kallikrein — Acute Stroke

XNCR · 2026-12-02

XMAB20717 — Biliary Tract Cancer

ARVN · 2026-12-04

ARV-471 — Healthy Participants

PFE · 2026-12-11

- — Urothelial Carcinoma

NVO · 2026-12-14

- — Overweight

ARVN · 2026-12-30

ARV-471 — Breast Cancer

PFE · 2026-12-30

ARV-471 — Breast Cancer

SUPN · 2026-12-30

BIS-001 — Focal Impaired Awareness Seizures

TCRX · 2026-12-30

- — Head and Neck Cancer

ACAD · 2026-12-31

ACP-204 — Autism Spectrum Disorder

ACTU · 2026-12-31

Losartan — Pancreatic Adenocarcinoma

ADAG · 2026-12-31

Pembrolizumab — Advanced Solid Tumor

ANNX · 2026-12-31

Tanruprubart — Guillain-Barre Syndrome

ARVN · 2026-12-31

ARV-471 — Breast Cancer

CERO · 2026-12-31

CER-1236 — AML

CMND · 2026-12-31

CMND-100 — Alcohol Use Disorder

CRNX · 2026-12-31

Atumelnant — Healthy Volunteers

PBYI · 2026-12-31

neratinib — Lung Cancer Metastatic

PFE · 2026-12-31

- — Lymphoma, Non-Hodgkin

REGN · 2026-12-31

Dupilumab — Asthma

RVMD · 2026-12-31

- — Non-small Cell Lung Cancer (NSCLC)

SUPN · 2026-12-31

- — Major Depressive Disorder (MDD)

TARS · 2026-12-31

TP-03 — Ocular Rosacea

VIR · 2026-12-31

Tobevibart — Viral Hepatitis

FBRX · 2026-12-31

FB102 — Vitiligo

ESLA · 2026-12-31

EB103 — B-Cell Non-Hodgkin's Lymphoma (NHL)

H1 2026 (est.)

CGON · H1 2026

Cretostimogene Grenadenorepvec — Non Muscle Invasive Bladder Cancer

DFTX · H1 2026

Psilocybin assisted therapy — Suicidal Ideation

NBP · H1 2026

TJ003234 — Coronavirus Disease 2019 COVID-19

AMLX · H1 2026

AMX0035 — Progressive Supranuclear Palsy

CNTB · H1 2026

TVRD · H1 2026

TTI-101 — Hepatocellular Carcinoma

H2 2026 (est.)

ANRO · H2 2026

EX-99

DFTX · H2 2026

Psilocybin assisted therapy — Suicidal Ideation

SION · H2 2026

SION-719 — Cystic Fibrosis (CF)

VRDN · H2 2026

VRDN-008

PHVS · H2 2026

deucrictibant — Hereditary Angioedema

EYPT · H2 2026

AURA · H2 2026

Bel-sar — Choroidal Melanoma

ZNTL · H2 2026

Investigator's choice of Chemotherapy — Ovarian Cancer

KPTI · H2 2026

EX-99

PCVX · H2 2026

31-valent pneumococcal conjugate vaccine — Pneumococcal Vaccines

NTLA-2002 — Hereditary Angioedema

FDMT · H2 2026

4D-150 IVT — Macular Neovascularization Secondary to Age-Related Macular Degeneration

bempikibart — Alopecia Areata

Q2 2026 (est.)

Tanruprubart — Guillain-Barre Syndrome

TENX · Q2 2026

TNX-103 — Pulmonary Hypertension Associated With HFpEF

Q3 2026 (est.)

ALMS · Q3 2026

Envudeucitinib — Plaque Psoriasis

AMLX · Q3 2026

AMX0035 — Progressive Supranuclear Palsy

ZURA · Q3 2026

Tibulizumab Dose A — Hidradenitis Suppurativa (HS)

TENX · Q3 2026

TNX-103 — Pulmonary Hypertension Associated With HFpEF

Q4 2026 (est.)

HELP · Q4 2026

CYB003 — Major Depressive Disorder (MDD)

CLDX · Q4 2026

Barzolvolimab — Chronic Inducible Urticaria

ATAI · Q4 2026

BPL-003

IRON · Q4 2026

DISC-1459 — Erythropoietic Protoporphyria

ZURA · Q4 2026

Tibulizumab Dose A — Hidradenitis Suppurativa (HS)

RGNX · Q4 2026

Ranibizumab — AMD

January 2027

ABBV · 2027-01-01

- — Myelodysplastic Syndromes (MDS)

ACAD · 2027-01-01

ACP-204 — Intermittent Explosive Disorder

CADL · 2027-01-01

Aglatimagene besadenovec + valacyclovir — Malignant Glioma of Brain

CALC · 2027-01-01

CM4620 — Acute Pancreatitis

CGEM · 2027-01-01

CLN-081 — Relapsed/Refractory Acute Myeloid Leukemia (AML)

LRMR · 2027-01-01

CTI-1601 — Friedreich Ataxia

MRK · 2027-01-01

- — Influenza

NRIX · 2027-01-01

NX-5948 — Chronic Lymphocytic Leukemia (CLL)

NUVL · 2027-01-01

Neladalkib — Locally Advanced Solid Tumor

ORKA · 2027-01-01

ORKA-001 — Healthy Volunteers

PCVX · 2027-01-01

31-valent pneumococcal conjugate vaccine — Pneumococcal Vaccines

RARE · 2027-01-01

Setrusumab — Osteogenesis Imperfecta

RCUS · 2027-01-01

- — Gastrointestinal Tract Malignancies

SGMT · 2027-01-01

Denifanstat — Acne

XENE · 2027-01-01

Azetukalner — Major Depressive Disorder

KURA · 2027-01-01

Ziftomenib — Solid Tumors With HRAS Alterations

IOVA · 2027-01-01

Lifileucel plus Pembrolizumab — Cervical Cancer

INAB · 2027-01-01

Autologous genetically modified gamma-delta T cells — Acute Myeloid Leukemia

GILD · 2027-01-01

- — Gastrointestinal Tract Malignancies

EWTX · 2027-01-01

- — Duchenne Muscular Dystrophy

OCUL · 2027-01-08

Otx-Tki — Neovascular Age-related Macular Degeneration

NVO · 2027-01-14

- — Overweight

AZTR · 2027-01-15

ATR04-484 — EGFR Inhibitor-associated Rash

MLTX · 2027-01-15

Sonelokimab — Arthritis, Psoriatic

XBIT · 2027-01-15

Methotrexate — Rheumatoid Arthritis

NTRA · 2027-01-21

- — Colon Adenocarcinoma

SGMT · 2027-01-25

Denifanstat — Prostatic Neoplasms, Castration-Resistant

MRK · 2027-01-29

Disitamab Vedotin — Urothelial Carcinoma

PFE · 2027-01-29

- — Urothelial Carcinoma

February 2027

ABCL · 2027-02-01

LY3819253 — Vasomotor Symptoms Associated With Menopause

AMLX · 2027-02-01

AMX0035 — ALS

SEPN · 2027-02-01

SEP-479 — Healthy Volunteers

XNCR · 2027-02-01

- — Clear Cell Renal Cell Carcinoma

KRYS · 2027-02-01

KB803 — Lung Cancer, Non-small Cell

KOD · 2027-02-01

KSI-101 — Macular Edema Secondary to Inflammation

IRON · 2027-02-01

DISC-1459 — Polycythemia Vera (PV)

IONS · 2027-02-01

- — Prion Disease

FBRX · 2027-02-01

FB102 — Healthy Volunteer

ENLV · 2027-02-01

Allocetra — Primary Knee Osteoarthritis

DNLI · 2027-02-01

- — Alzheimer Disease, Early Onset

MLTX · 2027-02-04

Sonelokimab — Arthritis, Psoriatic

NVCR · 2027-02-17

Temozolomide — Spinal Metastasis

MRK · 2027-02-26

MK-6482 — Renal Cell Carcinoma (RCC)

ABBV · 2027-02-28

- — Mantle Cell Lymphoma

FBRX · 2027-02-28

FB102 — Celiac Disease

March 2027

AGIO · 2027-03-01

Mitapivat Matched Placebo — Chondrosarcoma

BIIB · 2027-03-01

- — Parkinson Disease

BPTH · 2027-03-01

BP1001 in combination with Ventoclax plus decitabine — Acute Myeloid Leukemia, in Relapse

CGEN · 2027-03-01

COM701 — Ovarian Cancer

COGT · 2027-03-01

CGT9486 — Intrahepatic Cholangiocarcinoma (Icc)

MDGL · 2027-03-01

Resmetirom — Non-Alcoholic Fatty Liver Disease

NUVB · 2027-03-01

safusidenib — Advanced Solid Tumor

NVCT · 2027-03-01

- — Advanced Solid Tumor

NVO · 2027-03-01

- — Obesity

OCUL · 2027-03-01

Otx-Tki — Non-Proliferative Diabetic Retinopathy

PCVX · 2027-03-01

31-valent pneumococcal conjugate vaccine — Pneumococcal Vaccines

PEPG · 2027-03-01

PGN-EDODM1 — Myotonic Dystrophy 1

PMVP · 2027-03-01

rezatapopt — TP53 Y220C Mutation

STOK · 2027-03-01

zorevunersen — Dravet Syndrome

URGN · 2027-03-01

UGN-104 — Upper Urinary Tract Urothelial Carcinoma

VSTM · 2027-03-01

avutometinib — Mesonephric Gynecologic Cancer

IONS · 2027-03-01

Olezarsen — Severe Hypertriglyceridemia

GPCR · 2027-03-01

aleniglipron — Obesity, Overweight, or Chronic Weight Management

EWTX · 2027-03-01

- — Duchenne Muscular Dystrophy

DNLI · 2027-03-01

BIIB122 — Parkinson Disease

FBRX · 2027-03-10

FB102 — Alopecia Areata

TSHA · 2027-03-12

TSHA-101 — Infantile GM2 Gangliosidosis (Disorder)

TVTX · 2027-03-12

Pegtibatinase — Focal Segmental Glomerulosclerosis

RYTM · 2027-03-13

Setmelanotide — Hypothalamic Obesity

ZLAB · 2027-03-14

ZL-1109 — Thyroid Eye Disease (TED)

SNY · 2027-03-25

- — Hemophilia

ALT · 2027-03-31

Pemvidutide — Alcohol Liver Disease

CGON · 2027-03-31

Cretostimogene Grenadenorepvec — High-Risk Non-Muscle-Invasive Bladder Cancer

MSLE · 2027-03-31

SAT-3247 — Duchenne Muscular Dystrophy

RVMD · 2027-03-31

- — Non-Small Cell Lung Cancer (NSCLC)

TNGX · 2027-03-31

Abemaciclib — Non Small Cell Lung Cancer

April 2027

ABCL · 2027-04-01

LY3819253 — Healthy Volunteers

CLYM · 2027-04-01

Budoprutug — Systemic Lupus Erythematosus

MIRM · 2027-04-01

- — Primary Biliary Cholangitis

NKTX · 2027-04-01

NKX019 — Lupus Nephritis

RCUS · 2027-04-01

- — Pancreatic Ductal Adenocarcinoma

TLSA · 2027-04-01

Foralumab Nasal — Multiple System Atrophy

VSTM · 2027-04-01

avutometinib — Low-Grade Serous Ovarian Cancer

XENE · 2027-04-01

Azetukalner — Primary Generalized Tonic-Clonic Seizures

KPTI · 2027-04-01

Selinexor — Multiple Myeloma

KOD · 2027-04-01

KSI-101 — Macular Edema Secondary to Inflammation

AGEN · 2027-04-07

- — Metastatic Soft Tissue Sarcoma

JNJ · 2027-04-14

- — Carcinoma, Non-small-Cell Lung

MRK · 2027-04-29

MK-6482 — VHL - Von Hippel-Lindau Syndrome

AIM · 2027-04-30

Ampligen — Prostate Adenocarcinoma

RCUS · 2027-04-30

- — Prostate Adenocarcinoma

RLAY · 2027-04-30

RLY-2608 — PIK3CA Mutation

IOVA · 2027-04-30

Lifileucel plus Pembrolizumab — Bone Sarcoma

May 2027

BOLT · 2027-05-01

BDC-4182 — Gastric Cancer Adenocarcinoma Metastatic

CMPX · 2027-05-01

CTX-009 — Metastatic Biliary Tract Cancer

CRNX · 2027-05-01

Atumelnant — Congenital Adrenal Hyperplasia

TNGX · 2027-05-01

S095035 — MTAP-deleted Solid Tumors

VTRS · 2027-05-01

- — Female Contraception

XENE · 2027-05-01

Azetukalner — Major Depressive Disorder

JBIO · 2027-05-01

JADE101 — Healthy Volunteers (HV)

IOVA · 2027-05-01

Lifileucel plus Pembrolizumab — Uveal Melanoma

IBRX · 2027-05-01

- — Platinum-resistant Ovarian Cancer

IBIO · 2027-05-01

- — Overweight , Obesity

GILD · 2027-05-01

- — Non Small Cell Lung Cancer

GH · 2027-05-01

FOLFIRI+cetuximab — Metastatic Non-small Cell Lung Cancer

TELO · 2027-05-01

Zn-Telomir — Triple-Negative Breast Cancer (TNBC)

SLDB · 2027-05-06

SGT-003 — Duchenne Muscular Dystrophy

- — Colorectal Cancer

NVO · 2027-05-16

- — Heart Failure

IBRX · 2027-05-25

- — Relapsed B-Cell Non Hodgkin Lymphoma

OLMA · 2027-05-30

Palazestrant — Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

ZLAB · 2027-05-30

ZL-1310 — SCLC

RVMD · 2027-05-31

RMC-6236 — Non-small Cell Lung Cancer (NSCLC)

SRPT · 2027-05-31

- — Duchenne Muscular Dystrophy

June 2027

ABBV · 2027-06-01

- — Multiple Myeloma

ASND · 2027-06-01

TransCon CNP — Hypoparathyroidism

BMEA · 2027-06-01

icovamenib — Type 2 Diabetes

BNTX · 2027-06-01

- — Mpox (Monkeypox)

CRSP · 2027-06-01

CTX001 — Cardiovascular

CRVS · 2027-06-01

Soquelitinib — Atopic Dermatitis

KYMR · 2027-06-01

KT-621 — Atopic Dermatitis

LBRX · 2027-06-01

LB-102 — Schizophrenia

MANE · 2027-06-01

VDPHL01 — Androgenetic Alopecia (AGA)

MIST · 2027-06-01

Etripamil NS — Paroxysmal Supraventricular Tachycardia

NMRA · 2027-06-01

NMRA-335140 — Major Depressive Disorder

NTRA · 2027-06-01

- — Carcinoma, Hepatocellular

ORKA · 2027-06-01

ORKA-001 — Plaque Psoriasis

REGN · 2027-06-01

- — Solid Tumor, Adult

RVMD · 2027-06-01

- — Non-Small Cell Lung Cancer, NSCLC

RXRX · 2027-06-01

REC-2282 — Familial Adenomatous Polyposis

SLDB · 2027-06-01

SGT-003 — Catecholaminergic Polymorphic Ventricular Tachycardia

SVRA · 2027-06-01

Molgramostim — Autoimmune Pulmonary Alveolar Proteinosis

TNGX · 2027-06-01

TNG462 — PDAC

VRCA · 2027-06-01

Part 1: VP-315 3 Day Dosing/Week — Common Warts

VSTM · 2027-06-01

avutometinib — Pancreatic Ductal Adenocarcinoma (PDAC)

ZYME · 2027-06-01

- — Biliary Tract Neoplasms

KPTI · 2027-06-01

Selinexor — Myelofibrosis

IRON · 2027-06-01

DISC-1459 — Sickle Cell Disease

IONS · 2027-06-01

Olezarsen — Familial Chylomicronemia Syndrome

INBX · 2027-06-01

INBRX-106 — Triple Negative Breast Cancer

GILD · 2027-06-01

Sacituzumab Govitecan-Hziy — Triple Negative Breast Cancer

DNLI · 2027-06-01

- — Mucopolysaccharidosis II

SNY · 2027-06-07

- — Pneumococcal Immunization

BIIB · 2027-06-25

- — Muscular Atrophy, Spinal

ACRS · 2027-06-30

A-101 — Metastatic Pancreatic Ductal Adenocarcinoma

BLTE · 2027-06-30

Tinlarebant — Geographic Atrophy

MIRM · 2027-06-30

BJT-778 — Chronic Hepatitis D Infection

PBYI · 2027-06-30

neratinib — Hormone Receptor Positive HER-2 Negative Breast Cancer

RIGL · 2027-06-30

Fostamatinib Disodium — Mutant IDH1 Inhibitor Olutasidenib

INDP · 2027-06-30

Decoy20 — Solid Tumor, Adult

July 2027

ABBV · 2027-07-01

- — Myelodysplastic Syndrome (MDS)

ALVO · 2027-07-01

Eylea Hd — Diabetic Macular Edema

ANL · 2027-07-01

Buparlisib & Paclitaxel — Advanced Solid Tumor (Phase 1)

ARTV · 2027-07-01

Rituximab — Rheumatoid Arthritis

BHVN · 2027-07-01

BHV-1400 — IgA Nephropathy

BPTH · 2027-07-01

BP1001 in combination with Ventoclax plus decitabine — Solid Tumor, Adult

MESO · 2027-07-01

Rexlemestrocel-L — Degenerative Disc Disease

MRK · 2027-07-01

- — Healthy Participants

NVS · 2027-07-01

- — Ovarian Neoplasm Epithelial

Selinexor — Relapse Multiple Myeloma

KURA · 2027-07-01

Ziftomenib — KMT2A-rearranged

SNY · 2027-07-15

- — Multiple Sclerosis

ADAG · 2027-07-30

- — Advanced Liver Cancers

TPST · 2027-07-30

TPST-1120 — Advanced Liver Cancers

BTAI · 2027-07-31

Sublingual film containing dexmedetomidine — Schizophrenia

KYNB · 2027-07-31

- — Metastatic Castration-resistant Prostate Cancer

TGTX · 2027-07-31

Ublituximab — Multiple Sclerosis

August 2027

ACAD · 2027-08-01

ACP-204 — Major Depressive Disorder (MDD)

ARTV · 2027-08-01

AB-101 — Lupus Nephritis - WHO Class III

ASND · 2027-08-01

TransCon CNP — Advanced Solid Tumor

BHVN · 2027-08-01

BHV-8000 — Parkinson Disease

CLLS · 2027-08-01

UCART22 — B-cell Non-Hodgkin Lymphoma (B-NHL)

CLYM · 2027-08-01

Budoprutug — Immune Thrombocytopenia (ITP)

CRNX · 2027-08-01

Atumelnant — Carcinoid Syndrome

NVCR · 2027-08-01

Temozolomide — Adenocarcinoma of Lung

PVLA · 2027-08-01

QTORIN — Angiokeratomas

RARE · 2027-08-01

Triheptanoin — Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

SUPN · 2027-08-01

SPN-817 — Focal Onset Seizures

TLX · 2027-08-01

177Lu-TLX591 — Clear Cell Renal Cell Carcinoma (ccRCC)

TVTX · 2027-08-01

Pegtibatinase — Homocystinuria

VRCA · 2027-08-01

Part 1: VP-315 3 Day Dosing/Week — Common Warts

ZLAB · 2027-08-01

ZL-1310 — Solid Tumors

KPRX · 2027-08-01

KIO-301 — Retinitis Pigmentosa

JNJ · 2027-08-01

Talquetamab — Multiple Myeloma

IONS · 2027-08-01

ION582 — Angelman Syndrome

DFTX · 2027-08-01

DT120 — Autism Spectrum Disorder

IBRX · 2027-08-03

- — Sepsis

LCTX · 2027-08-10

AST-OPC1 — Spinal Cord Injury Cervical

VIR · 2027-08-16

VIR-5818 — Locally Advanced or Metastatic HER2-Expressing Cancers

VSTM · 2027-08-16

avutometinib — Thyroid Cancer

NVO · 2027-08-27

Etavopivat — Sickle Cell Disease

PMVP · 2027-08-27

rezatapopt — Myelodysplastic Syndrome

RADX · 2027-08-30

RAD101 — Imaging

BNTX · 2027-08-31

ONC-392 — Non Small Cell Lung Cancer

MIRM · 2027-08-31

Brelovitug — Chronic Hepatitis D

September 2027

AGEN · 2027-09-01

Botensilimab — Metastatic Colorectal Cancer

CHS-1420 — Hepatocellular Carcinoma

CLYM · 2027-09-01

Budoprutug — Systemic Lupus Erthematosus

Verekitug — Severe Asthma

ZYME · 2027-09-01

- — Hepatocellular Carcinoma

KTTA · 2027-09-01

PAS-004 — NF1 Mutation

IOVA · 2027-09-01

Lifileucel plus Pembrolizumab — Unresectable Melanoma

IONS · 2027-09-01

- — Multiple System Atrophy

HUMA · 2027-09-01

Human Acellular Vessel — Trauma

DFTX · 2027-09-01

DT120 — Major Depressive Disorder

ACXP · 2027-09-29

Ibezapolstat — Clostridium Difficile Infection Recurrence

VIR · 2027-09-29

VIR-5500 — Hormone-refractory Prostate Cancer

ACTU · 2027-09-30

ING-41 — Pancreatic Adenocarcinoma

CNTA · 2027-09-30

cleminorexton — Narcolepsy Type 1

October 2027

AGEN · 2027-10-01

Balstilimab — Metastatic Prostate Cancer

ALVO · 2027-10-01

- — Melanoma

CLYM · 2027-10-01

Budoprutug — Primary Membranous Nephropathy

CORT · 2027-10-01

Relacorilant — Metastatic Breast Cancer

MIRM · 2027-10-01

- — Fragile X Syndrome

NVCR · 2027-10-01

Temozolomide — Pancreas Cancer

OPK · 2027-10-01

CTAP101 — CKD Stage 3

ORKA · 2027-10-01

ORKA-001 — Plaque Psoriasis

Enobosarm & Abemaciclib Combo — Obesity & Overweight

JBIO · 2027-10-01

JADE101 — Rhematoid Arthritis

EYPT · 2027-10-01

EYP-1901 — Diabetic Macular Edema

EVMN · 2027-10-01

EVO756 — Migraine

VTRS · 2027-10-08

- — SLE - Systemic Lupus Erythematosus

PBYI · 2027-10-30

neratinib — Small Cell Lung Cancer

493 upcoming readouts. Source: ClinicalTrials.gov primary-completion estimates (month precision). Readout timing is not a guaranteed announcement date.